EP #364 - Reto Naef: Disruptive Therapies for Aging Diseases
Swisspreneur Show Timestamps:
13:03 - The birth of TOPADUR
18:07 - Leaving the cushy life for entrepreneurship
23:26 - TOPADUR’s drug development
30:36 - Financing pharma
38:08 - Sparks IPO Academy
About Reto Naef:
Reto Naef is the founder and former CEO of TOPADUR PHARMA AG, a biopharmaceutical company developing disruptive therapies for aging diseases. He holds a PhD in Chemistry from ETH and an MBA from UZH and previously worked for pharma companies like Sandoz and Novartis before starting TOPADUR in 2015.
TOPADUR develops dual-acting drugs that target the cGMP-Enzyme Regulation System to stimulate microcirculation, enable tissue regeneration, and avoid local oxygen deficiency. Based on this key invention, they’ve built a portfolio of drug candidates to treat aging-related diseases like chronic
0
(-)
Rate this episode:
Episode mentions
You can listen to this podcast, but not everything mentioned in it has been defined yet. Upvote it if you want it to be added next - the most voted podcasts will be added as soon as possible
Transcript
This episode has not been transcribed yet. Upvote it if you want it to be added next - the most voted podcasts will be added as soon as possible.